Administration Case Report With EXPAREL

This case report represents the individual experience of Dr Stan Dysart and is intended to demonstrate his methodology for using EXPAREL in a specific orthopedic procedure.

Pacira Pharmaceuticals, Inc. recognizes that there are alternative methodologies for administering local anesthetics, as well as individual patient considerations, when selecting the dose for a specific procedure. EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

### CASE INFORMATION

<table>
<thead>
<tr>
<th>Physician Name</th>
<th>Stan Dysart, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Affiliation</td>
<td>Pinnacle Orthopaedics/Wellstar Health System</td>
</tr>
<tr>
<td>Surgical Case Performed</td>
<td>Total knee arthroplasty (TKA)</td>
</tr>
<tr>
<td>Inpatient or Outpatient Procedure</td>
<td>Inpatient</td>
</tr>
</tbody>
</table>

### PATIENT CHARACTERISTICS

| Gender | Male |
| Age   | 81 years |
| Patient History and Characteristics | Patient previously underwent a successful left TKA |
| Pathology | Patient has right knee osteoarthritis and is now undergoing a right TKA with an ERAS protocol |

### PROCEDURAL DETAILS

| Incision Size | 15 cm |
| Preoperative Analgesics Used | AC block—20 mL of 0.25% bupivacaine with epinephrine |
| Intraoperative Analgesics Used | TIVA general—150-200 mcg/kg/min propofol titrated based on surgical needs; 50-100 mcg fentanyl as needed |
| Periarticular injection with 20 mL EXPAREL and 50 mL 0.25% bupivacaine |

<table>
<thead>
<tr>
<th>Dose of EXPAREL and Total Volume Used</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXPAREL (266 mg)</td>
</tr>
<tr>
<td>Bupivacaine HCl 0.25%</td>
</tr>
<tr>
<td>Normal Saline</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

AC, adductor canal; ERAS, enhanced recovery after surgery; TIVA, total intravenous anesthesia.

The recommended dose of EXPAREL is based on the size of the surgical site, the volume required to cover the area, and individual patient factors that may impact the safety of an amide local anesthetic. The maximum dose of EXPAREL should not exceed 266 mg.

EXPAREL can be administered unexpanded (20 mL) or expanded to increase volume up to a total of 300 mL (final concentration of 0.89 mg/mL [ie, 1:14 dilution by volume]) with normal (0.9%) saline or lactated Ringer’s solution.

Bupivacaine HCl may be administered immediately before EXPAREL or admixed in the same syringe, as long as the ratio of the milligram dose of bupivacaine HCl to EXPAREL does not exceed 1.2. Admixing may impact the pharmacokinetic and/or physiochemical properties of EXPAREL, and this effect is concentration dependent. The toxic effects of these drugs are additive and their administration should be used with caution, including monitoring for neurological and cardiovascular effects related to local anesthetic systemic toxicity. Other than with bupivacaine, EXPAREL should not be admixed with other drugs prior to administration.

Please see Important Safety Information on the last page and refer to the accompanying full Prescribing Information for complete Dosage and Administration information before using EXPAREL.
ASSESSED THE SIZE OF THE SURGICAL SITE AND DEPTH OF TISSUE, THEN PREPARED INJECTION MATERIALS ACCORDINGLY

In this procedure, Dr Dysart determined that a total volume of approximately 120 mL would be needed to cover the surgical site. He expanded 20 mL of EXPAREL® (bupivacaine liposome injectable suspension) with 50 mL of normal saline and admixed this solution with 50 mL of 0.25% bupivacaine. Dr Dysart added bupivacaine to provide short-term local analgesia in the postanesthesia care unit that overlapped with the long-term local analgesia provided by EXPAREL.

DIVIDED INJECTATE INTO SYRINGES WITH NEEDLE GAUGES APPROPRIATE FOR INFILTRATION (20- TO 25-GAUGE) AND PLANNED WHICH AREAS TO INFILTRATE WITH EACH INJECTION

For this procedure, Dr Dysart divided the injectate evenly into six 20-mL syringes using a 21-gauge needle and infiltrated as follows:

**PRIOR TO CEMENTATION**
- **Syringe #1:** Posterior capsule
- **Syringe #2:** Femur
- **Syringe #3:** Tibia, pes anserinus, medial collateral ligament (MCL), gutter
- **Syringe #4:** Circumferential periosteum

**AFTER CEMENTATION**
- **Syringe #5:** Quadriceps tendon, retinaculum, medial gutter
- **Syringe #6:** Lateral gutter, subcutaneous tissue

INFILTRATED AFTER THE BONY CUTS WERE PERFORMED

After completing the bony cuts, Dr Dysart inserted a laminar spreader between the cut femur and tibia, exposing the posterior capsule of the knee. He then proceeded with infiltrating the injectate as follows:

**Syringe #1:**
- Medial and lateral infiltration of the posterior capsule
  - Medial infiltration of posterior capsule with approximately 10 needle sticks to create a field block
  - Lateral infiltration of posterior capsule with approximately 10 needle sticks

**Syringe #2:**
- Medial and lateral infiltration of femoral periosteal/synovial tissues and of suprapatellar tissue with 20 needle sticks of 1 mL to 1.5 mL per injection
  - Inject until a noticeable bubble forms. It is normal for there to be more dramatic swelling in this thick, fibrous layer than when soft tissue is infiltrated.

**Syringe #3:**
- Injection of fat pad, pes anserinus, MCL, and medial gutter, saturating the area

**Syringe #4:**
- Medial and lateral infiltration of the circumferential periosteum of the tibia using 15 to 20 needle sticks

**Syringe #5:**
- Injection of the synovial tissue beneath the quadriceps tendon and the retinacular tissue medially from the femur to the tibia

**Syringe #6:**
- Injection of the lateral gutter and the lateral retinacular tissue from the femur to the tibia
  - Injection of the lateral gutter and the lateral retinacular tissue from the femur to the tibia. Residual volume is used in the subcutaneous tissue medially and laterally. There will likely be swelling of the tissue from fluid volume

Before each injection, be sure to aspirate to minimize the risk of intravascular injection. Be sure not to inject too far laterally, and monitor the volume injected because of the proximity of the peroneal nerve.

When infiltrating, stay in the tissue to reduce the amount of extravasation.

Please see Important Safety Information on the last page and refer to the accompanying full Prescribing Information for complete Dosage and Administration information before using EXPAREL.
PROPER TECHNIQUE IS CRUCIAL FOR ANALGESIC COVERAGE

When infiltrating EXPAREL® (bupivacaine liposome injectable suspension), Dr Dysart makes sure to infiltrate below the fascia, above the fascia, and into the subcutaneous tissue using a moving needle technique. With a moving needle technique, the injections are spread in a rapid and precise fan-like pattern to maximize the number of injection areas. The tissues are infiltrated as the needle is advanced and withdrawn to maximize the coverage area. This technique should be systematically and meticulously repeated with each subsequent injection site, and the next site should overlap with the prior infiltrated area to maximize effect.

Watch Dr Dysart infiltrate with EXPAREL at www.EXPAREL.com

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death.

Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Disclosure: Dr Dysart is a paid consultant for Pacira Pharmaceuticals, Inc.